BR112013015085A2 - composição farmacêutica, método para preparar uma composição, e, uso de composição - Google Patents

composição farmacêutica, método para preparar uma composição, e, uso de composição

Info

Publication number
BR112013015085A2
BR112013015085A2 BR112013015085A BR112013015085A BR112013015085A2 BR 112013015085 A2 BR112013015085 A2 BR 112013015085A2 BR 112013015085 A BR112013015085 A BR 112013015085A BR 112013015085 A BR112013015085 A BR 112013015085A BR 112013015085 A2 BR112013015085 A2 BR 112013015085A2
Authority
BR
Brazil
Prior art keywords
composition
preparing
pharmaceutical
pharmaceutical composition
Prior art date
Application number
BR112013015085A
Other languages
English (en)
Other versions
BR112013015085A8 (pt
Inventor
Benigno C Valdez
Borje S Andersson
Jeffery Terrand
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of BR112013015085A2 publication Critical patent/BR112013015085A2/pt
Publication of BR112013015085A8 publication Critical patent/BR112013015085A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
BR112013015085A 2010-12-16 2011-12-16 Composição farmacêutica, método para preparar uma composição, e, uso de composição BR112013015085A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42393710P 2010-12-16 2010-12-16
US201161509154P 2011-07-19 2011-07-19
PCT/US2011/065422 WO2012083138A2 (en) 2010-12-16 2011-12-16 Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds

Publications (2)

Publication Number Publication Date
BR112013015085A2 true BR112013015085A2 (pt) 2016-08-09
BR112013015085A8 BR112013015085A8 (pt) 2018-04-03

Family

ID=46245384

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013015085A BR112013015085A8 (pt) 2010-12-16 2011-12-16 Composição farmacêutica, método para preparar uma composição, e, uso de composição

Country Status (16)

Country Link
US (2) US10307418B2 (pt)
EP (1) EP2651450B1 (pt)
JP (2) JP6086539B2 (pt)
CN (1) CN103402543B (pt)
AU (1) AU2011343576B2 (pt)
BR (1) BR112013015085A8 (pt)
CA (1) CA2821823C (pt)
DK (1) DK2651450T3 (pt)
ES (1) ES2565353T3 (pt)
HK (1) HK1190643A1 (pt)
HU (1) HUE028667T2 (pt)
IL (1) IL226977A (pt)
MX (1) MX337364B (pt)
NZ (1) NZ613167A (pt)
RU (2) RU2734128C2 (pt)
WO (1) WO2012083138A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028667T2 (en) * 2010-12-16 2016-12-28 Borje S Andersson Parenteral administration of azole pharmaceutical compositions for use in treating diseases susceptible to azole compounds and methods for their preparation.
CA2834262C (en) * 2011-04-28 2020-08-25 Borje S. Andersson Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same
RU2015111684A (ru) * 2012-12-28 2017-02-02 Сантори Холдингз Лимитед Безалкогольный напиток со вкусом пива, имеющий shimari во вкусе
CN105394045B (zh) * 2014-09-04 2020-02-14 中国科学院上海巴斯德研究所 一种肠道病毒的小分子化合物抑制剂及其应用
CN105943500B (zh) * 2016-07-08 2019-01-04 河南省立眼科医院 一种含有艾沙康唑的眼用纳米胶束抗真菌溶液
AU2020225663B2 (en) * 2019-02-19 2024-03-14 Laboratorios Salvat, S.A. Single-dose packaged clotrimazole liquid composition
CN111665301A (zh) * 2020-05-29 2020-09-15 南京品生医疗科技有限公司 超高效液相色谱串联质谱技术检测血清中抗真菌药物的试剂盒
CN113671086B (zh) * 2021-08-31 2023-06-16 重庆华邦制药有限公司 分离、测定泊沙康唑z2及其杂质的方法
CN114660200A (zh) * 2022-03-29 2022-06-24 中国人民解放军总医院 一种高效液相色谱串联质谱技术同时测定血浆中4种三唑类抗真菌药物的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4912124A (en) 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
DE3702105A1 (de) 1987-01-24 1988-08-04 Bayer Ag Parenterale loesung
JPH01242525A (ja) * 1988-03-25 1989-09-27 Nippon Nohyaku Co Ltd 抗真菌外用剤
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
TW349870B (en) * 1993-09-30 1999-01-11 Janssen Pharmaceutica Nv An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
KR0159730B1 (ko) * 1996-01-15 1998-12-01 손경식 케토코나졸 수성 제제
US7179475B1 (en) * 1998-12-04 2007-02-20 Johnson & Johnson Consumer Companies, Inc. Anhydrous topical skin preparations
US6362172B2 (en) * 2000-01-20 2002-03-26 Bristol-Myers Squibb Company Water soluble prodrugs of azole compounds
GB2365770B (en) * 2000-08-18 2002-07-31 Diomed Dev Ltd Antifungal ketoconazole composition for topical use
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
JP2002322056A (ja) * 2001-04-27 2002-11-08 Nippon Kayaku Co Ltd トリアゾール誘導体の溶液製剤
JP4263441B2 (ja) * 2002-08-07 2009-05-13 富士重工業株式会社 ４輪駆動車の制御装置
WO2004014431A1 (en) * 2002-08-12 2004-02-19 Ranbaxy Laboratories Limited A parenteral dosage form of selective cox-2 inhibitors
ZA200409537B (en) 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US20060003654A1 (en) * 2004-06-30 2006-01-05 Lostocco Michael R Dispersible alcohol/cleaning wipes via topical or wet-end application of acrylamide or vinylamide/amine polymers
EP1863481A1 (en) * 2005-03-31 2007-12-12 Brystol-Myers Squibb Company Methods for administering ixabepilone
EP1895843A4 (en) * 2005-06-27 2010-06-02 Stiefel Laboratories MICOGEL TOPICAL FORMULAS
WO2007047253A2 (en) 2005-10-11 2007-04-26 Eastman Chemical Company Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
EP2097065A2 (en) * 2006-11-29 2009-09-09 Foamix Ltd. Foamable waterless compositions with modulating agents
CN101808637B (zh) 2007-09-05 2013-07-24 宝丽制药股份有限公司 医药组合物
US20090253712A1 (en) * 2008-04-03 2009-10-08 Semmelweis Egyetem Aqueous solvent system for solubilization of azole compounds
WO2009139925A1 (en) * 2008-05-16 2009-11-19 Panacea Pharmaceuticals, Inc. Methods for the treatment of brain edema
WO2010090654A1 (en) 2009-02-05 2010-08-12 Tdt, Ltd. Methods of reducing the proliferation and viability of microbial agents
US10130610B2 (en) 2009-04-09 2018-11-20 Pola Pharma Inc. Antimycotic pharmaceutical composition
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
HUE028667T2 (en) * 2010-12-16 2016-12-28 Borje S Andersson Parenteral administration of azole pharmaceutical compositions for use in treating diseases susceptible to azole compounds and methods for their preparation.
CA2834262C (en) * 2011-04-28 2020-08-25 Borje S. Andersson Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

Also Published As

Publication number Publication date
AU2011343576A1 (en) 2013-07-11
CN103402543A (zh) 2013-11-20
JP2017114869A (ja) 2017-06-29
RU2618456C2 (ru) 2017-05-03
JP6529527B2 (ja) 2019-06-12
WO2012083138A3 (en) 2012-11-01
RU2016149770A3 (pt) 2020-02-04
DK2651450T3 (en) 2016-03-14
BR112013015085A8 (pt) 2018-04-03
RU2013132703A (ru) 2015-01-27
EP2651450B1 (en) 2015-12-16
US20140031366A1 (en) 2014-01-30
MX337364B (es) 2016-02-29
HK1190643A1 (zh) 2014-07-11
HUE028667T2 (en) 2016-12-28
JP6086539B2 (ja) 2017-03-01
CA2821823C (en) 2019-05-07
RU2734128C2 (ru) 2020-10-13
WO2012083138A2 (en) 2012-06-21
CA2821823A1 (en) 2012-06-21
IL226977A (en) 2017-01-31
US20190240216A1 (en) 2019-08-08
JP2013545819A (ja) 2013-12-26
AU2011343576B2 (en) 2016-09-08
EP2651450A2 (en) 2013-10-23
NZ613167A (en) 2015-09-25
EP2651450A4 (en) 2014-07-09
MX2013006816A (es) 2013-11-01
US10307418B2 (en) 2019-06-04
ES2565353T3 (es) 2016-04-04
RU2016149770A (ru) 2018-11-05
CN103402543B (zh) 2015-09-16

Similar Documents

Publication Publication Date Title
BRPI0922174A2 (pt) preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica
BRPI1010775A2 (pt) composição, método para preparar uma composição, e, uso de uma composição.
BRPI1011764A2 (pt) composição farmacêutica, e, método para preparar uma composição farmacêutica
BR112014003802A2 (pt) composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014001255A2 (pt) composto, uso de um composto, combinação, e, composição farmacêutica
BR112014015042A2 (pt) composição farmacêutica, e, método para obter uma composição radiofarmacêutica
BR112012026570A2 (pt) composto, composição farmacêutica, uso de um composto, método para o tratamento de um indíviduo e produto combinado
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013015816A2 (pt) construção de dna para imunomodulação, composição farmacêutica, vacina e uso de uma construção de dna
BR112014001346A2 (pt) composto nanotransportador, método, composto farmacêutico e uso de um composto
BR112013015085A2 (pt) composição farmacêutica, método para preparar uma composição, e, uso de composição
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112012002102A2 (pt) composição farmaceutica e metodo para preparar uma composição farmaceutica
BR112014011671A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição, e, uso de um composto
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112015002091A2 (pt) método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BR112014007645A2 (pt) composto heterocíclico, métodos para a preparação de um composto heterocíclico, e, composição farmacêutica
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112014013177A2 (pt) composto, composição farmacêutica e uso de um composto
BR112013013581A2 (pt) composição de graxa, componente mecânico, uso da composição de graxa, e, método para preparação de uma composição de graxa
BRPI0922173A2 (pt) preparação farmacêutica, e, método para preparar uma preparação farmacêutica
BR112014013178A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014017445A2 (pt) composição, uso de uma composição, corpo lignocelulósico, e, método para preparar uma composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/496 (2006.01), A61K 9/00 (2006.01), A61K 4

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: BORJE S. ANDERSSON, JEFFREY TARRAND E BENIGNO C. V

B25A Requested transfer of rights approved

Owner name: PLATFORM BRIGHTWORKS TWO, LTD. (US)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time